Shandong Danhong Pharmaceutical Co., Ltd.

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Other

Medshine Discovery Inc.

Shandong Luye Pharmaceutical Co., Ltd.

Guangzhou Consun Pharmaceutical Co. Ltd

Zhixiang Li

Shuhui Chen

Wentao Wu

Jian Li

Jian Qin

Jie Li

Guangwen Yang

Fei Wang

Yang Zhang

Wei Gu

Bing Deng

Zhen Gong

Jikui Sun

Fei Hong

Juan Yu

Jinming Huang

Zhiliang Chen

Tingting Yin

Jiahu Wu

Jinxia Lin

Wenyuan Zhu

Jinxiang Zeng

Limei Yang

Wenliang Lan

Liju Wang

Mingxing Teng

Yongbo Fang

The use of a phenylpropionamide compound in the preparation of a drug for treating diseases associated with pain and pruritus. Specifically, the present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt thereof.

Phenylpropionamide compound and use thereof

The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.

Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases

An amorphous form of dezocine analogue hydrochloride is represented by formula (II). An X-ray powder diffraction spectrum of the amorphous form is shown in FIG.

Crystal form and amorphous form of dezocine analogue hydrochloride

Disclosed in the present invention are a crystal form of a TrkA inhibitor and a preparation method thereof, and an application thereof in preparation of drugs for treating diseases associated with pain, cancer, inflammation, neurodegenerative diseases, and certain infectious diseases.

Crystal form of pyrrolidinyl urea derivative and application thereof

Disclosed is a method for preparing a pyrrolidinyl urea derivative, which acts as a TrkA inhibitor, and further disclosed are an intermediate compound of a compound of formula (I) and a preparation method therefor.

Method for preparing pyrrolidinyl urea derivative

The present invention relates to a crystal form and an amorphous form of dezocine analogue hydrochloride, and in particularly, to a crystal form of a compound represented by formula (I) and an amorphous form of a compound represented by formula (II). An X-ray powder diffraction spectrum of the crystal form comprises characteristic peaks at 2&#x3b8; values of 13.1&#xb0;&#xb1;0.2&#xb0;, 16.8&#xb1;0.2&#xb0;, and 18.5&#xb1;0.2&#xb0;, and an X-ray powder diffraction spectrum of the amorphous form is shown in FIG.

Disclosed are an angiotensin II receptor 2 (ATR) antagonist salt form and crystalline form, a preparation method therefor, and an application of the salt form and crystalline form in preparing a drug which treats chronic pain. 

Angiotensin II receptor 2 antagonist salt form and crystalline form, and preparation method therefor

The present invention relates to a series of 2,6-dioxaspiro [4,5] decane derivatives and applications thereof in preparation of opiate receptor &#x3bc; agonist related drugs; and in particular relates to the derivative compounds shown in formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof. 

2,6-dioxaspiro [4,5] decane derivatives and preparation method therefor and pharmaceutical applications thereof

The present invention relates to a compound shown in formula (II) or a pharmaceutically acceptable salt thereof and an application of the same in preparing a drug for treating a disease related to angiotensin II receptor type 2 (ATR).(II) 

Carboxylic acid derivative as ATR receptor antagonist

Disclosed are a sustained release suspension containing dezocine analogue ester and a preparation method therefor. According to the present invention, an injectable oily auxiliary material which may pharmaceutically serve as a sustained-release depot and an excipient are selected, and micronization technology is used jointly with high pressure homogenization technology and an anti-solvent technique to prepare an injectable long-acting suspension. The main components of the suspension are a compound represented by formula (I), the injectable oil, and the like. 

Sustained release suspension containing dezocine analogue ester and preparation method therefor

Disclosed in the present disclosure is a Dezocine analog, and particularly disclosed are compounds represented by formula (I), (II) and (III), a pharmaceutically acceptable salt or tautomer thereof. 

Growing community of inventors

Shanghai, China

Zhixiang Li